In September 2019, the Company's Board of Directors (the Board) adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, PSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board and is generally four years from the date of grant or, for grants to new hires, four years from the date of hire. As described below, the Board also awards PSUs to executive officers that vest upon the occurrence of performance milestones. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. Pursuant to the evergreen provision, on January 1, 2026, an additional 916,463 shares of the Company's common stock became available for issuance under the 2019 Plan. As of June 30, 2026, 1,427,318 shares of the Company's common stock remained available for future awards under the 2019 Plan.

As of June 30, 2026, all of the 1,973,952 outstanding RSUs were unvested. The fair value of RSUs vested in the six months ended June 30, 2026 and 2025 was $1.4 million and $1.3 million, respectively. The weighted-average grant date fair value per share for RSUs granted during the six months ended June 30, 2026 and 2025 was $3.18 and $3.97 per RSU, respectively. As of June 30, 2026, total unrecognized compensation cost related to RSUs was $6.4 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.6 years.

In May 2026, as part of its long-term incentive plan, the Company granted a total of 800,000 PSUs to its executive officers which vest contingent upon the achievement of pre-determined market conditions and service conditions. The number of shares of common stock to be issued at vesting for these awards is calculated based on the

Company's relative total shareholder return (TSR) percentile rank measured against the Russell 2000 Index during three overlapping measurement windows which occur over a three-year period from the grant date. Vesting with respect to the TSR percentile rank ranges from zero to 200 percent of the target number of PSUs, with a maximum aggregate of 1,600,000 PSUs that may be earned. The PSUs cliff-vest at the end of the three-year period, subject to the achievement of both the market and service conditions. As of June 30, 2026, all 800,000 PSUs remained outstanding and unvested.

The Company determined the grant-date fair value of the PSUs using the Monte Carlo simulation model, which calculates the fair value of each PSU by estimating the probability of satisfying the market conditions stipulated in the awards. The assumptions used in the Monte Carlo simulation model are as follows:

The Company recognizes stock-based compensation expense for the PSUs ratably over the three-year performance period of the awards. The weighted-average grant date fair value per share of the PSUs granted during the six months ended June 30, 2026 was $5.64 per PSU. As of June 30, 2026, total unrecognized compensation cost related to the PSUs was $4.3 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.9 years.


	Number of Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2025	526,839	$	6.86	6.48	$	957
Granted	433,700	$	3.81

Forfeited	(19,000)	$	5.37
Expired	(10,033)	$	12.81
Outstanding, June 30, 2026	931,506	$	5.41	7.59	$	908
Vested and expected to vest, June 30, 2026	931,506	$	5.41	7.59	$	908
Options exercisable, June 30, 2026	419,054	$	7.42	5.07	$	449

There were 433,700 and 169,570 stock options granted in the six months ended June 30, 2026 and 2025, respectively. The weighted-average grant date fair value per share for options granted during the six months ended June 30, 2026 and 2025 was $2.69 and $3.50, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. No options were exercised during the six months ended June 30, 2026, and the aggregate intrinsic value of options exercised during the six months ended June 30, 2025 was zero. As of June 30, 2026, total unrecognized compensation cost related to option awards was $1.3 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.1 years.

In September 2019, the Board adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Board. The ESPP permits participants to purchase shares of the Company's common stock through payroll deductions of up to 20.0% of their eligible compensation. The number of shares of the Company's common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the

lesser of (i) 1.0% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. Pursuant to the evergreen provision, on January 1, 2026, an additional 229,115 shares of the Company's common stock became available for issuance under the ESPP. As of June 30, 2026, 675,900 shares of the Company's common stock remained available for issuance under the ESPP. During the six months ended June 30, 2026, a total of 96,023 shares of the Company's common stock were issued under the ESPP.